N-Butyl-L-Deoxynojirimycin (L-NBDNJ): Synthesis of an allosteric enhancer of α-glucosidase activity for the treatment of Pompe disease
The highly stereocontrolled de novo synthesis of L-NBDNJ (the unnatural enantiomer of the iminosugar drug Miglustat) and a preliminary evaluation of its chaperoning potential are herein reported. L-NBDNJ is able to enhance lysosomal α-glucosidase levels in Pompe disease fibroblasts, either when admi...
Main Authors: | D'Alonzo, D, De Fenza, M, Porto, C, Iacono, R, Huebecker, M, Cobucci-Ponzano, B, Priestman, D, Platt, F, Parenti, G, Moracci, M, Palumbo, G, Guaragna, A |
---|---|
Format: | Journal article |
Published: |
American Chemical Society
2017
|
Similar Items
-
Structure of human lysosomal acid α-glucosidase–a guide for the treatment of Pompe disease
by: Véronique Roig-Zamboni, et al.
Published: (2017-10-01) -
Carnitine is a pharmacological allosteric chaperone of the human lysosomal α-glucosidase
by: Roberta Iacono, et al.
Published: (2021-01-01) -
<i>N</i>-Nonyloxypentyl-<span style="font-variant: small-caps">l</span>-Deoxynojirimycin Inhibits Growth, Biofilm Formation and Virulence Factors Expression of <i>Staphylococcus aureus</i>
by: Eliana De Gregorio, et al.
Published: (2020-06-01) -
α-Glucosidase inhibition of lactone intermediates of the iminosugar deoxynojirimycin
by: Wai Haan, Y, et al.
Published: (2019) -
Synthesis and biological characterisation of novel N-alkyl-deoxynojirimycin alpha-glucosidase inhibitors.
by: Rawlings, A, et al.
Published: (2009)